Фемостон 2

Quick links

Choose a section

Quick links to important sections

Advertisements

Фемостон 2

Advertisements
Advertisements

Overview of Фемостон 2

Quick Facts

Property Description
Active Ingredients Estradiol and Dydrogesterone
Form Film-coated tablets
Pharmacological Class Estrogens/Progestogens (Combination HRT)
Common Use Hormone replacement for postmenopausal women
Origin Combination of naturally occurring and synthetic components

What Type of Medicine is Фемостон 2?

Фемостон 2 is a prescription-only medicine that is classified as a Hormone Replacement Therapy (HRT) preparation, belonging to the pharmacological class of Estrogens/Progestogens in combination. This dual-hormone preparation is specifically designed for postmenopausal women to address symptoms associated with oestrogen deficiency, a purpose that is widely recognized in clinical practice. It is defined as a Sequential Combined HRT, distinguishing it from continuous regimens; this format means the active ingredients are formulated into film-coated tablets for oral administration in a specific sequence that results in expected, periodic uterine bleeding.

What is the Composition of Фемостон 2?

The medication is a Combination product containing the two active ingredients Estradiol and Dydrogesterone. The Estradiol component is supplied as estradiol hemihydrate, which is structurally identical to the most potent, naturally occurring Estrogen produced by the ovaries. The second component, Dydrogesterone, is a structurally specific synthetic progestogen, included in the formulation to provide a key protective effect. The unique chemical structure of Dydrogesterone enables its role as an orally active progestogen in this combination.

Why Does Фемостон 2 Contain Two Active Ingredients?

The inclusion of both Estradiol and Dydrogesterone is essential for fulfilling the primary general purpose of this therapy in women with an intact uterus. The Estradiol component serves to replenish depleted estrogen levels, thereby addressing the systemic effects of oestrogen deficiency that can occur after menopause. Concurrently, the Dydrogesterone component, acting as a Progestogen, prevents the development of excessive thickening and overstimulation of the uterine lining (endometrial hyperplasia), which is a known risk when estrogen is used alone. This strategic combination is clinically recognized for ensuring a protective and balanced approach to hormone replacement.

Regulatory References

  1. Dydrogesterone MeSH Descriptor Data
Advertisements

What side effects are possible with Фемостон 2?

Possible Side Effects and Safety Information

The safety profile for this combined Hormone Replacement Therapy (HRT) is organized by the frequency and physiological system affected, based on official regulatory classifications.


Frequency-Classified Adverse Reactions

Adverse reactions documented in official labeling are grouped by expected occurrence:

  • Very Common (≥ 1/10): Reactions like headache, abdominal pain, and breast pain or tenderness are frequently reported.
  • Common (≥ 1/100 to < 1/10): These include migraine, dizziness, nausea, flatulence, weight increase, and irregular uterine bleeding or spotting.

Irregular bleeding or spotting is explicitly noted to be more common during the first months of treatment.


Serious Associated Safety Risks

The use of combined HRT is associated with certain serious risks documented in regulatory warnings:

  • Thromboembolic Events: An increased risk of developing Venous Thromboembolism (VTE), including Deep Vein Thrombosis and Pulmonary Embolism, is documented. This risk is more likely during the first year of HRT.
  • Cardiovascular Events: Increased risk of Stroke and Myocardial Infarction.
  • Malignancy Risk: An increased risk of Breast Cancer and Ovarian Cancer is associated with combined HRT. The increased risk of Breast Cancer is typically tied to longer durations of exposure.

Population and Contextual Safety Notes

Official safety documents include considerations for specific contexts:

  • Intact Uterus: The inclusion of the progestogen component is mandatory for women with an intact uterus to mitigate the risk of Endometrial Hyperplasia.
  • Geriatric Use: For postmenopausal women aged 65 years or older, there is a documented increased risk of developing probable dementia.

Use of this medicine is restricted (Contraindicated) in individuals with known or suspected breast cancer, a history of active VTE, or severe liver disease.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding overdosage with Femoston 2/10 (estradiol/dydrogesterone) indicates that the active components have a very low acute toxicity. Consequently, serious harm is generally considered unlikely following ingestion of a dose higher than prescribed.

Documented Overdose Manifestations

Symptoms that have been reported in cases of overdosage are typically mild and transient. These are primarily related to the gastrointestinal and reproductive systems and may include:

  • Nausea and vomiting
  • Breast tenderness
  • Dizziness or drowsiness/fatigue
  • Abdominal pain
  • Withdrawal bleeding (may occur a few days after the overdose)

Overdose Management and Action

According to official regulatory guidance, the management of a Femoston 2 overdose is generally symptomatic, as no specific antidote is available. No specific medical treatment is usually required given the low toxicity profile.

Action Required Guidance based on Regulatory Documents
Antidote No specific antidote exists.
Treatment Treatment is symptomatic; often, no specific medical intervention is necessary.
Urgency Serious effects are unlikely, but contact a healthcare professional for advice if you are worried about the overdose.

Population Considerations

The information regarding low toxicity is also generally applicable to cases of accidental overdosage in children. The experience with overdose treatment in patients over 65 years of age remains limited.

Advertisements

Therapeutic Uses of Фемостон 2

Фемостон 2 (Femoston 2), a form of combined Hormone Replacement Therapy (HRT), is commonly used to help manage the symptomatic discomfort and systemic imbalance associated with menopause. Its primary purpose is to address the hormonal decline that naturally occurs, thus supporting patients during episodes of heightened discomfort and contributing to easing the overall symptom load.

The main benefits of this class of medicine include relief from disruptive menopausal symptoms and support for long-term bone health.

The therapeutic application of this medicine is primarily focused on treating symptoms of oestrogen deficiency in postmenopausal women. This includes addressing the classic vasomotor symptoms like hot flushes, night sweats, and providing assistance with other manifestations such as mood swings and the prevention of osteoporosis.

Quick Fact: Support for Vasomotor Symptom Management The medicine is commonly used to help manage symptoms related to heightened physiological activity, like hot flushes and night sweats.


Symptomatic Relief of Menopause

This therapeutic domain addresses the symptom clusters that become more noticeable and may lead to functional strain, particularly those related to heightened physiological activity and physical discomfort.

Applied in contexts where additional symptomatic support is needed, Фемостон 2 is used in settings where symptoms become momentarily overwhelming. The medicine is relevant in contexts marked by increased discomfort or tension. It provides supportive relief that helps patients cope more steadily with difficult episodes, contributing to improved day-to-day comfort.


Support for Bone Health and Stability

This domain focuses on managing long-term systemic imbalance, which is commonly associated with acute or disruptive episodes affecting bone integrity.

The medicine is relevant in situations involving recurrent or episodic manifestations, and is considered applicable in conditions where functional stability becomes affected, such as managing long-term bone health. It assists with maintaining functional stability of the bones by providing supportive relief relevant in contexts marked by increased discomfort or tension.

Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Фемостон 2 (Estradiol/Dydrogesterone) is officially indicated solely for postmenopausal women to treat oestrogen deficiency symptoms. Since it is a combined Hormone Replacement Therapy (HRT), it is required for women who have an intact uterus, as the Dydrogesterone component provides crucial endometrial protection. The medicine is also indicated for the prevention of postmenopausal osteoporosis in women at high risk of future fractures who cannot use non-oestrogen options.


Contraindicated Populations

Use of this medicine is strictly contraindicated in patients who have or are suspected of having breast cancer or other oestrogen-dependent malignant tumours. Absolute non-eligibility also applies to those with undiagnosed genital bleeding, untreated endometrial hyperplasia, acute liver disease, a history of venous thromboembolism (VTE), arterial thromboembolic disease (e.g., recent stroke or heart attack), or known thrombophilic disorders.


Age and Physiological Restrictions

Pregnancy and breastfeeding are statuses where use is either contraindicated or not indicated, and treatment must be immediately withdrawn if pregnancy is suspected. The medicine is not for use in the pediatric population, and experience in treating women older than 65 years is officially limited. Patients with certain conditions, such as diabetes mellitus or hypertension, require close supervision.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Фемостон 2 (estradiol/dydrogesterone) has an official interaction profile determined primarily by pharmacokinetic interactions that alter the plasma concentrations of its active hormonal components.


Pharmacokinetic Interactions

Interactions are generally classified based on their effect on the CYP3A4 metabolic enzyme system, which processes both estradiol and dydrogesterone. The regulatory description of these interactions is detailed in official government documents:

  • Exposure Reduction (Enzyme Induction): Co-administration with medicinal products that induce CYP3A4 activity leads to a reduced systemic exposure of estradiol and dydrogesterone. Substances documented to cause this effect include the anticonvulsants phenytoin, carbamazepine, and phenobarbital, and the anti-infectives rifampicin and rifabutin. The herbal product St. John's Wort (Hypericum perforatum) is also documented as an enzyme inducer that reduces exposure.

  • Exposure Increase (Enzyme Inhibition): Co-administration with strong CYP3A4 inhibitors is documented to result in increased systemic exposure of the active components. This effect is seen with strong azole antifungals such as ketoconazole, which formally raises the plasma concentrations of estradiol and dydrogesterone.

No mandatory timing separation requirements or absolute combination contraindications, solely due to interaction risk, are uniformly stated across primary regulatory labels for this product.

Advertisements

Mechanism of Action

How Фемостон 2 Works

Фемостон 2 is composed of estradiol and dydrogesterone, acting as a sequential hormonal combination. The estradiol component is a 17beta-estradiol, functioning as an agonist at nuclear Estrogen Receptors ( ERalpha and ERbeta). Ligand binding to these receptors initiates their dimerization, translocation to the nucleus, and subsequent modulation of gene transcription. This process affects various cellular functions in target tissues, including the central nervous system and bone.

In bone tissue, estradiol modulates the expression of cytokines and signaling molecules, primarily inhibiting the activity of osteoclasts and supporting osteoblast function, which shifts the bone remodeling balance towards accretion. The dydrogesterone component, a retroprogesterone derivative, acts as a selective agonist of the Progesterone Receptor (PR). In the uterus, dydrogesterone binds to PRs in the endometrial cells, inducing a full secretory transformation. This action counteracts the proliferative stimulation of the endometrium mediated by estradiol, leading to a regulated shedding and stabilization of the uterine lining structure. This dual-component mechanism facilitates two distinct, yet coordinated, pharmacological actions: ER-mediated transcriptional modulation and PR-mediated cellular differentiation.

Advertisements

Dosage and Administration Information

How to Use Фемостон 2

Фемостон 2 (Femoston 2/10) is administered according to a continuous sequential Hormone Replacement Therapy (HRT) regimen, meaning the two active ingredients, estradiol and dydrogesterone, are taken in a fixed sequence over a defined period. This administration protocol is designed to standardize use.

Official Administration Protocol

Instruction Category Official Guideline
Route of Administration Oral use
Daily Dose One film-coated tablet taken once daily.
Dosing Principle Treatment should utilize the lowest effective dose for the shortest duration.
Food Relationship May be taken with or without food (irrespectively of food intake).
Dosing Schedule Taken over a 28-day cycle with no break between packs.

Sequential Dosing Structure

The 28-day cycle is divided into two distinct periods based on the tablet composition:

  1. Days 1–14 (Estrogen Phase): One tablet containing 2 mg estradiol is taken daily.
  2. Days 15–28 (Combined Phase): One tablet containing 2 mg estradiol plus 10 mg dydrogesterone is taken daily.

The medication should be taken at about the same time each day to maintain consistency.

Handling Missed Doses

Standard protocols specify a critical threshold for forgotten tablets: if a tablet is missed, it should be taken as soon as possible. However, if more than 12 hours have elapsed since the usual time, the forgotten tablet must be skipped, and the patient should resume the cycle with the next scheduled dose.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Hormone Therapy Research

Фемостон 2 is a form of continuous combined hormone therapy (HRT) containing estradiol and dydrogesterone. Research focuses on evaluating its role in the management of symptoms associated with the menopause in women with an intact uterus. This combination aims to provide menopausal symptom relief while including a progestogen to help mitigate the risk of endometrial hyperplasia or cancer that may be associated with unopposed estrogen use.

Study Focus on Vasomotor Symptoms

Multiple clinical studies, including randomized trials, have investigated the effects of this formulation on common menopausal symptoms. A primary area of research is the effect on vasomotor symptoms (VMS), such as hot flashes and night sweats.

Studies have consistently reported data concerning a reduction in the frequency and severity of hot flashes among participants receiving the drug compared to baseline, which is a common finding across most HRT regimens. Researchers recorded the change in VMS frequency over periods typically ranging from 12 weeks to one year.

Endometrial Safety and Bone Density

The dydrogesterone component is included in the therapy to protect the uterine lining. Trials have focused on monitoring the endometrial safety profile, observing data related to bleeding patterns and endometrial thickness over treatment cycles. These studies typically compare this formulation to other HRT types or placebo regarding its impact on the endometrium.

Additionally, research has investigated the effects of the estrogen component on bone mineral density in postmenopausal women. Findings often report data related to the maintenance or improvement of bone mass density in comparison to a placebo or untreated group, aligning with the recognized effect of estrogen on bone health.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Фемостон 2 (FAQ)


Q: How long does it usually take to notice an effect after starting Фемостон 2?

A: Official guidance indicates that hormone replacement therapy (HRT) may take time to achieve its full therapeutic effect on symptoms. Treatment effectiveness is commonly reviewed by a medical professional three to six months after initiation to assess the drug's impact on menopausal symptoms.

Q: Can Фемостон 2 be used by women who have had a hysterectomy?

A: Фемостон 2 is a combined HRT, containing both estrogen and a progestogen. Official product information states that combined HRT is specifically required for women who still have an intact uterus to protect the womb lining. Women who have had a hysterectomy (removal of the uterus) are generally prescribed estrogen-only HRT, as the progestogen component is included primarily for uterine protection.

Q: Is there any research evidence on the long-term use of Фемостон 2?

A: Regulatory guidance emphasizes that HRT treatment must utilize the lowest effective dose for the shortest duration. Official warnings highlight that the documented increased risk of certain conditions, such as breast cancer, is associated with longer-term use of combined HRT.

Q: Is there a maximum amount of time a person can be on Фемостон 2?

A: Official information states that treatment should be prescribed for the shortest duration to control symptoms. The need for continued treatment must be reassessed at least once per year by a medical professional, following an appropriate physical examination.

Q: What are the eligibility requirements for someone to be considered for Фемостон 2?

A: Фемостон 2 is indicated for postmenopausal women to address symptoms caused by oestrogen deficiency and to prevent postmenopausal osteoporosis. Regulatory documents state that a complete medical history and physical examination, including specific checks on blood pressure and breasts, are required before initiating the medicine.

Q: Is it necessary to have regular check-ups while taking Фемостон 2?

A: Regulatory documents indicate that patients taking HRT are typically required to have a review and check-up at least once per year. This process is essential for supervision and generally includes regular breast examinations and mammography, as recommended by official guidelines.

Q: What does the research say about Фемостон 2 and sleep quality?

A: While the main focus of clinical evidence is often on vasomotor symptoms, government-sponsored trial registries show that studies involving the estradiol/dydrogesterone combination have included the assessment of related outcomes. These studies have specifically investigated sleep problems and fatigue.

Q: What are the descriptive expectations regarding the return of menstrual periods while on Фемостон 2?

A: As a sequential combined HRT, the regimen is structured to produce a predictable withdrawal bleed. This bleeding is expected to occur around the end of each 28-day tablet cycle. Official safety information also notes that irregular bleeding or spotting is a common side effect, especially during the first few months of use.

Q: How does Фемостон 2 compare to Фемостон 1 or Фемостон 1/5?

A: These formulations represent different strengths of the same medicine. Official prescribing information states that Фемостон 2 contains 2 mg of estradiol throughout the cycle, whereas other strengths contain lower doses, such as 1 mg. The specific dose prescribed is determined by a medical professional based on the individual's symptom severity.

Q: Are there specific vitamins or supplements that interact with Фемостон 2?

A: Official documents explicitly list the herbal product St. John’s Wort as a substance that may interact with the medicine. It acts as an enzyme inducer, potentially reducing the amount of Фемостон 2’s active ingredients in the body. Other common vitamins and supplements are not typically listed as pharmacokinetic interactions in the official documents.

Q: Does using Фемостон 2 mean I can't drink coffee or alcohol?

A: Official documents generally do not list coffee as an interaction factor. While no strict, uniform restrictions on alcohol are noted across primary regulatory labels, general safety advice from some sources suggests using caution and avoiding excessive alcohol consumption while on the treatment.

Q: What is the difference between sequential and continuous HRT, and where does Фемостон 2 fit?

A: Фемостон 2 is a sequential combined HRT. In this regimen, estrogen is taken daily, and progestogen is added for a specific number of days in each cycle, resulting in an expected monthly withdrawal bleed. Continuous combined HRT involves taking both hormones every day without a planned break, which is generally designed to result in no periodic bleeding.

Q: Can Фемостон 2 affect mood or energy levels?

A: Official safety information lists fatigue (tiredness) as a common side effect of the medicine. Regulatory documents also note that mood disorders, such as depression or nervousness, have been reported in association with the use of hormone replacement therapy.

Q: Can I stop taking Фемостон 2 if I feel better?

A: Official product information states that the medicine should not be stopped without first discussing it with the prescribing medical professional. The duration of therapy is subject to regular review by a healthcare provider.

Q: Is it described in official documents that Фемостон 2 can affect liver function?

A: Yes. Official documents list acute liver disease or a history of liver disease where function is not normal as a contraindication for use. Regulatory guidance indicates that the medicine should be discontinued immediately if a patient develops signs of jaundice or a deterioration of liver function.

Q: Is there a link between Фемостон 2 and blood pressure?

A: Yes. Hypertension (high blood pressure) is listed as a condition that requires a patient to be closely monitored during treatment. Official warnings state that the medicine must be discontinued if a significant and sustained increase in blood pressure is observed.

Q: What is the risk profile of Фемостон 2 in patients with a history of migraines?

A: Migraine is listed as a common adverse reaction and is a condition for which a patient with a pre-existing history requires close supervision. Official warnings state that treatment must be discontinued immediately upon the new onset of a migraine-type headache.

Q: Are there any official warnings about driving or operating machinery while using Фемостон 2?

A: Official patient information generally indicates that the medicine is not expected to affect the ability to drive. However, side effects such as dizziness and fatigue have been reported, which may temporarily affect the ability to operate machinery or drive safely.

Q: Why is it important to take the tablets in the correct sequence?

A: The sequential structure is necessary because the estrogen component, used alone in a woman with an intact uterus, can stimulate excessive thickening of the womb lining (endometrial hyperplasia). The progestogen component, taken later in the sequence, is required to counteract this stimulation and provide protection.

Q: Can Фемостон 2 cause changes to vision or eye health?

A: Official safety information lists changes in vision as a serious side effect that requires immediate medical consultation. Furthermore, regulatory documents state that contact lens intolerance (changes in corneal curvature) has also been reported in association with HRT use.

Q: Is Фемостон 2 described in official literature as being affected by body weight?

A: Regulatory documents list obesity as a risk factor that must be managed appropriately during treatment, particularly due to the increased risk of venous thromboembolism (VTE). While dosage is generally determined by symptom severity, close clinical monitoring is indicated for patients with obesity.

Q: Does the time of day matter when taking Фемостон 2?

A: Official regulatory guidelines state that the medicine should be taken at about the same time each day. This practice is advised to help maintain consistent levels of the active hormones in the body.

Q: What research themes are currently being explored regarding Фемостон 2?

A: Research involving the estradiol/dydrogesterone combination continues, often listed in government-sponsored clinical trial registries. These studies focus on collecting long-term efficacy and safety data, as well as refining continuous hormonal therapies for women during the perimenopausal period.

Q: Are there any specific laboratory tests that are affected by Фемостон 2?

A: Official product information indicates that the medicine may interfere with the results of certain laboratory tests. These include tests for coagulation parameters and thyroid-binding globulin levels. Patients must inform laboratory personnel they are taking this medicine before any testing.

Q: Does Фемостон 2 contain any ingredients that are known allergens?

A: Official Patient Information Leaflets list the active and inactive ingredients (excipients). Hypersensitivity (an allergic reaction) to either the active or inactive ingredients is listed as a contraindication for use.

Q: Are there specific food restrictions listed when taking Фемостон 2?

A: The medicine can generally be taken with or without food. However, official drug records for the dydrogesterone component suggest that grapefruit juice may increase the blood levels of certain medications, and consumption may be limited.

Q: What kinds of evidence are used by regulatory bodies to assess Фемостон 2?

A: Regulatory assessment is based on a comprehensive review of multiple types of evidence. This includes detailed findings from clinical trials (e.g., randomized studies on efficacy), pharmacokinetic data detailing drug processing, and non-clinical studies (e.g., toxicology data) to determine the overall risk-benefit profile.

Q: Is it possible to develop an allergy to the ingredients in Фемостон 2?

A: Yes. Hypersensitivity (an allergic reaction) to either the active ingredients (estradiol or dydrogesterone) or any of the inactive ingredients is listed as a strict contraindication. Official safety information advises seeking immediate medical attention if signs of a serious allergic reaction, such as swelling of the face or throat, occur.

Advertisements

How should Фемостон 2 be stored and disposed of?

Storage and Disposal Requirements

Official Storage Conditions

For Femoston 2 mg tablets, the maximum storage temperature is strictly defined by regulatory documents. The medicine must be stored at a temperature below 30 C and kept in a cool, dry place. It is required that the product be protected from excessive heat and moisture to maintain the stability of the active ingredients. The tablets must remain in their original container and blister packaging until the time of use.

Child Safety and Waste Handling

It is a mandatory requirement to keep this medicine out of the sight and reach of children at all times. For disposal, unused or expired Femoston 2 must not be thrown into wastewater or household waste, as the product may pose a risk to the aquatic environment. Disposal must be performed according to local regulatory requirements or by returning the unused medicine to a pharmacy or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фемостон 2 found in:

A-Z Index: